Table 3.
Phase II and retrospective studies of Nilotinib in metastatic / recurrent GIST.
| Study | Study Type | Number of patients |
Results |
|---|---|---|---|
| Cauchi, C., et,br/>al | Phase II | 13 | Majority of the responses were stable disease, 7.7% (1) PR by Choi criteria. 61% (8) PD by RECIST and 38.5 %( 5) PD by Choi criteria. |
| Sawaki, A., et al. |
Phase II | 35 | 3% PR, 66% SD. Median PFS of 113 days and OS of 310 days. |
| Montemurro, M., et al. |
Retrospective analysis |
52 | 47 evaluable patients. 10% had SD, 2% CR, 8.5% PR. Median PFS 12 weeks Median OS 34 weeks. Median survival from the first diagnosis of GIST was 72 months. |